Ge Rui Nong Biotech completing tens of millions of Pre-A round financing to accelerate innovation and global layout of bacteriophage pesticides

A few days ago, Ge Rui Nong Biotech, a Chinese bacteriophage biomanufacturer, announced completion of tens of millions of Pre-A round financing. This round of financing will be mainly used to accelerate the bacteriophage product innovation and certification process for the purpose of applications to multiple scenarios. It is reported that the company’s Pre-A+ round financing is underway as well.

In 2022, Ge Rui Nong Biotech already set up a scientific research team working in the field of plant protection, thereby to develop plant-based products for control of bacterial diseases utilizing the bacteriophage technology. After two years of market research and technical breakthroughs, the company could successfully put its bacteriophage product series to industrialization, for control of major plant diseases like bacterial wilt and canker, which are already released to market this year. These products serve as new biocontrol solutions, which are of help to reduction of use of chemical pesticides and alleviation of environmental impact, having contributed to promotion of the sustainable agricultural development.

So far, Ge Rui Nong Biotech has provided a number of breeding industry leaders with precise and efficient phage solutions. With the expansion of business and the growth of market share, the company’s business revenue in 2024 increased by nearly 100% year on year. Moreover, in this year, Ge Rui Nong Biotech has set up an overseas business department dedicated to development of international market in South America and Southeast Asia, as a response to the global demand for green farming, which is also a promotion to globalization of Chinese bacteriophage technology.